ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2019 July Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2019
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2351 - 2360 လၢ 3563 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P58-19 Updated Minnesota Health Care Programs and Minnesota Senior Health Options (MSHO) Prior Authorization and Medical Policy Requirements
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P57-19 New Medical, Medical Drug and Behavioral Health Policy Management Updates for Commercial and Medicare Advantage Lines of Business
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP64-19 Platinum Blue Choice Member Copays
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 26, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP65-19 Denial, Termination, Reduction (DTR) Notices not Generated
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 26, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP62-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Interleukin 5 (IL-5) Inhibitors
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 26, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP60-19 2019 Blue Cross Basic Seminars
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 26, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP61-19 Availity Portal Authorization Frequently Asked Questions
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 26, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP63-19 When the Authorization Tool is Utilized on the Availity Portal
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 26, 2019
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP58-19 Pharmacy Benefit Exclusion for Zolgensma (onasemnogene abeparvovec-xioi) Injection
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 12, 2019